Pharmacology
-
There is evidence that both cholinergic and GABAergic systems are involved in the neurobiology of anxiety. In the present study, we investigated the effects and interaction of nicotinic and GABAergic systems in the central amygdala of rats, using the elevated plus maze test of anxiety. Bilateral administration of nicotine (1 and 2 microg/rat; 1 microl/rat; 0.5 microl/rat in each side) into the central amygdala (intra-CeA) induced an anxiogenic-like effect, shown by specific decreases in the percentage of open-arm time (%OAT) and percentage of open arm entries (%OAE). ⋯ Nicotine in a subeffective dose (0.25 microg/rat) when co-administered with muscimol did not significantly increase the anxiety behaviour. An effective dose of nicotine (2 microg/rat) in combination with bicuculline (0.25, 0.5 and 1 microg/rat) had no interaction on %OAT, %OAE and locomotor activity. It can be concluded that in the central amygdala, the GABAergic system is not involved in the anxiogenic response to nicotine.
-
There is considerable research evidence supporting a palliative role for gamma-aminobutyric acid (GABA)-ergic neurotransmission and voltage-gated sodium channel blockade in neuropathic pain conditions. Hence, the present study was undertaken to assess the peripheral analgesic, antiallodynic and antihyperalgesic activities of the synthesized structural analogues of GABA. ⋯ In this study, we have demonstrated that combining phthalimide pharmacophore with GABA has evolved compounds effective for the treatment of neuropathic pain.
-
The present study was designed to investigate the role of strychnine-sensitive glycine receptors in hypnosis and analgesia induced by emulsified volatile anesthetics. After having established the mice model of hypnosis and analgesia by intraperitoneally injecting (i.p.) appropriate doses of ether, enflurane, isoflurane or sevoflurane, we intracerebroventricularly (i.c.v.) or intrathecally (i.t.) injected different doses of strychnine and then observed the effects on the sleeping time using the awaken test and the pain index in hot-plate test (HPPI) using the hot-plate test. In the awaken test, strychnine 1, 2, 4 microg (i.c.v.) had no distinctive effect on the sleeping time of the mice treated with the four emulsified inhalation anesthetics mentioned above (p > 0.05); in the hot-plate test, strychnine 0.1, 0.2, 0.4 microg (i.t.) can significantly and dose-dependently decrease the HPPI of the mice treated with emulsified ether, enflurane and sevoflurane (p < 0.05, p < 0.01); strychnine 0.1 microg (i.t.) did not affect the HPPI of the mice treated with emulsified isoflurane (p > 0.05), but 0.2 and 0.4 microg (i.t.) can significantly decrease the HPPI of the mice treatedwith emulsified isoflurane (p < 0.05, p < 0.01). These results suggest that strychnine-sensitive glycine receptors may contribute to the analgesic but not to the hypnotic effects induced by ether, enflurane, isoflurane and sevoflurane.
-
Using a new animal model of postoperative pain we recently developed, we investigated whether the selective cyclooxygenase-2 (COX-2) inhibitor parecoxib sodium, and the analgesic tramadol hydrochloride, attenuated mechanical primary hyperalgesia induced by minor surgery on the rat tail. ⋯ We have shown that the hyperalgesia in our model of postoperative pain is responsive to treatment with the analgesic tramadol, but it is not responsive to the selective COX-2 inhibitor parecoxib at the doses we used.